Company / Cash & Equivalents
Bausch & Lomb Corp Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$383.0M
FY2025
5-year range
$174.0M / $383.0M
FY2021-FY2025
Trend
+25.6%
vs FY2024
Sector context
#55 of 152
Health Care
What the data says
At $383M, Bausch & Lomb Corp's cash & equivalents ranks #55 of 152 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $383M.
Based on SEC 10-K filings.
$383M in FY2025 with a 3-year CAGR of +2.7%.
Improved from $331M to $383M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +2.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#55 of 152 in Health CareTop 36% of 152This company $383.0M Sector average $1.2B
▼
-67.4% below sector average
Key checks
Key Insights
- 3-year CAGR of +2.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 25.6% year-over-year.
- Ranks #55 out of 152 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.74 (distress zone, below 1.8 threshold)
- Negative profit margin: -6.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $383.0M | +25.6% |
| FY2024 | $305.0M | -7.9% |
| FY2023 | $331.0M | -6.5% |
| FY2022 | $354.0M | +103.4% |
| FY2021 | $174.0M | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026